Allulose, sometimes labeled D-allulose or D-psicose, is a rare sugar that occurs naturally in small quantities in foods such as figs, raisins, and jackfruit. Chemically, it is a C-3 epimer of fructose, meaning it shares fructose’s molecular formula but differs in the spatial orientation of a single hydroxyl group. That tiny structural difference has large metabolic consequences: allulose is poorly digested in the small intestine, contributes negligible calories, and does not meaningfully raise blood glucose or insulin. It has attracted growing attention as a bulk sweetener for sugar-reduced beverages and foods, and recent work has explored how gut microbes can even utilize it as a substrate. Yet while its glycemic profile is well documented, rigorous human evidence that allulose can actively improve rehydration, rather than simply avoid harming it, has been scarce.

The new study, led by Hye Rim Kim and Jinsoo Noh of Samyang Corporation together with colleagues at Yonsei University in South Korea, set out to fill that gap with a carefully controlled human trial. Fifteen healthy men completed the protocol, which used a randomized, double-blind, crossover design widely regarded as the gold standard for nutrition interventions. In a crossover trial, each participant serves as his own control, experiencing both experimental conditions in randomly assigned order with a washout period in between. This design minimizes the noise created by individual differences in sweat rate, fitness, and baseline hydration, which are substantial in fluid-balance research. Neither the participants nor the investigators knew which beverage was consumed on a given trial day, protecting the results from expectation effects.

The experimental challenge was deliberately physiological. Each participant first underwent exercise-induced dehydration, losing body water through physical exertion in a controlled setting, before consuming one of two electrolyte-matched beverages. The drinks were identical in their electrolyte content, so the only meaningful variable was the sweetener: one contained allulose, while the control beverage was sweetened with sucralose, a non-nutritive sweetener that provides sweetness without any carbohydrate transport activity. By matching electrolytes and holding volume constant, the researchers isolated the specific contribution of allulose to the rehydration process. The team then tracked an extensive panel of outcomes, including plasma volume recovery, fluid retention, thirst ratings, body water composition measured by bioelectrical impedance analysis, urine specific gravity, blood glucose, and body temperature.

The headline result was striking. Plasma volume, the liquid component of blood that supports cardiovascular function and thermoregulation during exercise, recovered far more completely in the allulose condition. Participants who drank the allulose beverage showed a plasma volume recovery of roughly 28 percent relative to their post-exercise deficit, compared with only about 4 percent after the sucralose drink, a difference the authors report as statistically significant at p = 0.0001. Fluid retention told a similar story: the allulose drink allowed the body to hold onto approximately 91.5 percent of the ingested fluid, whereas the sucralose control retained about 80.6 percent, a gap of more than ten percentage points that reached significance at p = 0.0023. In practical terms, the allulose beverage did not just quench thirst; it kept the water inside the body where it could do physiological work.

Subjective thirst followed the objective measurements. Participants reported a significantly greater reduction in thirst after the allulose beverage, with a mean thirst reduction score of 6.47 compared with 4.60 for the control, significant at p = 0.0012. This matters because thirst is a surprisingly poor guide to true rehydration. People often stop drinking once oral sensations fade, long before plasma volume and cellular hydration are fully restored, a phenomenon that contributes to chronic mild dehydration in athletes and ordinary people alike. A beverage that both relieves thirst and measurably improves fluid retention addresses both the behavioral and the physiological sides of the problem. Notably, the researchers found no glycemic cost: blood glucose was not adversely affected, and there was no thermoregulatory penalty, meaning the sugar did not interfere with the body’s temperature control after exercise.

Why would a poorly digested sugar enhance fluid retention at all? The most plausible mechanism, which the authors situate within existing literature, involves sodium-glucose cotransport. The intestinal transporter SGLT1 couples the uptake of glucose and sodium, and in doing so creates an osmotic gradient that pulls water across the gut lining. Research on this transporter has shown it is an extraordinarily efficient facilitator of passive water movement, which is precisely why oral rehydration solutions for illness rely on glucose and sodium in balanced proportions. Although allulose is only partially absorbed, some transport activity appears sufficient to augment water uptake and, critically, to help retain absorbed fluid within the vascular and cellular compartments rather than letting the kidneys excrete it rapidly. The kidney’s own sodium-glucose cotransport systems may also contribute to keeping filtered water in the body.

The study’s measurement strategy adds credibility to these conclusions. Bioelectrical impedance analysis allowed the team to distinguish total body water, extracellular water, and intracellular water, offering a window into where the retained fluid actually resided. Urine specific gravity served as a standard clinical index of hydration status, reflecting how concentrated the kidneys are making urine; a lower value after rehydration indicates the body is conserving water rather than dumping it. Combining these objective markers with plasma volume estimates and subjective thirst scales gives a more complete picture than any single measure could, and the consistency across outcomes strengthens the case that the effect is real rather than a statistical artifact.

Several caveats deserve attention. The sample comprised fifteen healthy men, so the findings cannot yet be generalized to women, older adults, or clinical populations, and the modest sample size, while typical for crossover metabolic studies, means the confidence intervals around the effect estimates are wide. The trial was funded by Samyang Corporation, which provided the study material, and most of the authors are affiliated with the company; the disclosure is transparent, but independent replication will be important before the results are treated as settled. The comparison sweetener, sucralose, was a sensible inert control, but future work comparing allulose directly against glucose-based sports drinks would clarify whether it matches or exceeds the gold standard, not merely whether it beats a non-transported sweetener. Doses, timing, and effects during exercise rather than after it also remain open questions.

Even with those limitations, the implications are compelling. Sports nutrition guidelines have long emphasized that fluid replacement after exercise should account for electrolyte losses and that carbohydrate can aid absorption, but the caloric arithmetic has always been awkward for the vast majority of people who exercise for health rather than performance. Sugar-sweetened beverages are firmly implicated in the global rise of obesity and type 2 diabetes, while purely non-nutritive sweeteners have faced persistent questions about metabolic effects. Allulose occupies a genuinely different position: it tastes and behaves like a sugar in formulation, it is metabolically stable and largely excreted or fermented rather than converted to energy, and this trial now provides human evidence that it can actively enhance plasma volume recovery and fluid retention after dehydration. If larger independent trials confirm these findings, the rehydration aisle could be reshaped by a rare sugar that most consumers have never heard of, one that helps the body hold onto water without holding onto calories.

Subject of Research: Effects of allulose on post-exercise rehydration and plasma volume recovery in humans

Article Title: Allulose enhances plasma volume recovery and fluid retention after exercise-induced dehydration: a randomized, double-blind, crossover trial

Article References: Allulose enhances plasma volume recovery and fluid retention after exercise-induced dehydration: a randomized, double-blind, crossover trial. (n.d.). https://doi.org/10.1007/s10068-026-02329-z

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02329-z

Keywords: allulose, rehydration, dehydration, plasma volume, fluid retention, exercise, rare sugar, sports nutrition, sucralose, crossover trial, sodium-glucose cotransport, low-calorie sweetener

The biological story begins with mitophagy, the selective autophagic disposal of damaged mitochondria. When this quality-control system falters, worn-out mitochondria linger in the cell and leak their DNA into the cytoplasm. Cytosolic mitochondrial DNA is not inert debris; it acts as a damage-associated molecular pattern that mimics a viral invasion. The cell’s innate immune surveillance machinery, chiefly the cyclic GMP–AMP synthase–stimulator of interferon genes pathway, better known as cGAS–STING, detects the misplaced DNA and ignites inflammatory and degenerative programmes. In the context of the disc, where cells already endure a harsh, nutrient-poor and acidic environment, this false alarm can push them over the edge into senescence and apoptosis.

What makes the new work distinctive is the identification of a downstream effector that translates this innate immune activation into actual cell fate decisions. Through integrated transcriptomic screening across degenerative, STING-inhibited and D-allose-treated conditions, the researchers converged on adrenomedullin 2, or ADM2, a bioactive peptide of the calcitonin gene-related peptide family also known as intermedin. ADM2 had previously been recognised for anti-apoptotic, anti-inflammatory and stress-adaptive functions in other tissues, but its role in the disc was unknown. The team found that ADM2 expression is progressively lost in severely degenerated human disc specimens, restored when cGAS–STING signalling is dampened, and functionally required for nucleus pulposus cells to resist senescence and apoptosis.

The evidence chain is unusually complete. In human tissue, the researchers collected 30 intervertebral disc samples from patients with a mean age of about 48 years, graded by the Pfirrmann system, and showed by immunohistochemistry that ADM2 fades as degeneration advances. In cell culture, oxidative stress induced by hydrogen peroxide and inflammatory stress induced by tumour necrosis factor both suppressed ADM2 at the mRNA and protein levels, while simultaneously driving up senescence markers such as p16, p21 and γH2AX, elevating the senescence-associated secretory phenotype marker IL-6, and flipping the Bax/Bcl-2 balance toward apoptosis with cleaved caspase-3 activation. D-allose treatment reversed essentially all of these changes.

The mechanistic core of the paper lies in the mitochondria. Under intense oxidative or inflammatory stress, the mitophagy apparatus visibly broke down: levels of the mitophagy proteins PINK1 and Parkin fell, the LC3-II/LC3-I ratio dropped, and the autophagic substrate p62 accumulated. Immunofluorescence revealed cytosolic double-stranded DNA piling up in stressed cells, and quantitative PCR of the mitochondrial gene MT-ND1 in cytosolic fractions confirmed that mitochondrial DNA had escaped into the cytoplasm. D-allose restored the mitophagy protein dynamics, curtailed the cytosolic mtDNA burden, and thereby starved the cGAS–STING pathway of its danger signal, as shown by reduced cGAS expression and diminished phosphorylation of STING, TBK1 and IRF3.

Pharmacological and genetic experiments then nailed down causality. When the researchers activated STING with the agonist diABZI, the protective effects of D-allose on senescence and apoptosis markers were abolished. Conversely, inhibiting STING with H-151 phenocopied the sugar’s benefits. The decisive experiment came from mice engineered to lack STING specifically in nucleus pulposus tissue, generated by crossing Sting1-floxed animals with Col2a1-Cre mice. In an annulus fibrosus puncture model of disc degeneration, these knockout mice were markedly resistant to disc height loss, MRI signal deterioration and histological disorganisation. Crucially, giving D-allose to STING-deficient mice provided no additional protection, indicating that the sugar works predominantly through this pathway rather than through some unrelated rescue route.

The in vivo results are the headline act. Systemic D-allose administration at 100 milligrams per kilogram per day, given intraperitoneally for two weeks before and two weeks after disc puncture, significantly ameliorated degenerative changes in C57BL/6 mice. T2-weighted MRI showed improved disc hydration and lower Pfirrmann grades, micro-CT revealed preserved disc height, and histological staining with haematoxylin–eosin and safranin O demonstrated partial restoration of nucleus pulposus architecture. At the matrix level, D-allose reversed the degenerative shift in which the anabolic components COL2A1 and aggrecan decline while the fibrotic COL1A1 accumulates, restoring a healthier extracellular matrix profile. RNA sequencing and Gene Ontology enrichment analysis independently confirmed that extracellular matrix terms and senescence pathways were the transcriptomic signatures most responsive to the treatment.

Functional studies of ADM2 itself rounded out the picture. In mouse discs, ADM2 expression declined progressively with ageing, hinting that its insufficiency may contribute to age-related degeneration. In cultured cells, silencing ADM2 with small interfering RNA was sufficient on its own to induce senescence markers, pro-apoptotic proteins and measurable increases in SA-β-gal positivity and Annexin V–positive apoptotic populations. Enforced ADM2 overexpression did the opposite, shielding stressed cells from senescence and death. Most tellingly, knocking down ADM2 substantially abolished D-allose’s ability to suppress senescence markers and rebalance apoptotic signalling, establishing the peptide as a required mediator of the sugar’s cytoprotection rather than a mere bystander.

Why does the choice of molecule matter so much? Current clinical strategies for disc degeneration largely manage symptoms rather than disease mechanisms, and existing drug candidates for long-term use often carry toxicity or metabolic burdens that limit chronic administration. D-allose, by contrast, is an ultra-low-calorie rare sugar with documented negligible toxicity in animal studies and reported anti-oxidative, anti-inflammatory and anti-apoptotic effects across diverse disease models. Its dual identity as both a bioactive stress-modulating molecule and a potential sugar substitute makes it especially attractive for ageing populations, where cumulative drug toxicity is a serious clinical concern. Rather than acting as a conventional pathway inhibitor, the authors argue, D-allose re-establishes cellular homeostasis by coordinately restoring mitochondrial quality control, limiting mtDNA-driven innate immune activation and preserving ADM2-dependent cytoprotection.

The authors are candid about the limits of the work. The molecular mechanisms governing ADM2 regulation remain to be defined, mitophagy-independent routes of mtDNA reduction may also contribute, and the pharmacokinetics of D-allose in disc tissue were not examined. Given the avascular nature of the intervertebral disc, future studies must determine how the sugar actually reaches the tissue, along with optimal dosing, treatment windows and long-term safety in humans. Still, the conceptual payoff is substantial: a unified framework in which mitophagy failure, cytosolic mitochondrial DNA, cGAS–STING activation and ADM2 silencing converge to decide the fate of disc cells, and a demonstration that this entire axis is therapeutically reversible with a safe, naturally derived molecule. If the findings translate, the humble rare sugar sitting at the edge of the sweetener aisle could become an unexpected ally in the fight against the back pain that afflicts hundreds of millions worldwide.

Subject of Research: D-allose reprogramming of the mitophagy–mtDNA–cGAS–STING–ADM2 axis in intervertebral disc degeneration

Article Title: D-allose reprogrammes the mitophagy–mtDNA–cGAS–STING–ADM2 axis to restore nucleus pulposus cell homeostasis in intervertebral disc degeneration

Article References: Zhao, Z., Li, J., Lei, L., Chen, Y., Li, Z., Zhang, Y., Zheng, Z., Wang, H., Chen, F., & Wang, J. (2026). D-allose reprogrammes the mitophagy–mtDNA–cGAS–STING–ADM2 axis to restore nucleus pulposus cell homeostasis in intervertebral disc degeneration. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01844-7

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01844-7

Keywords: D-allose, intervertebral disc degeneration, mitophagy, mitochondrial DNA, cGAS-STING, ADM2, nucleus pulposus cells, senescence, apoptosis, innate immunity, rare sugar, low back pain

D-tagatose is what chemists call a rare sugar, a hexose isomer found only in trace amounts in nature. It carries roughly the same sweetness as sucrose but with a very low caloric value, and a growing body of nutritional literature has linked it to beneficial effects on blood glucose control, making it attractive for diabetic-friendly foods and beverages. It has also drawn attention for its antimicrobial potential against oral bacteria, a property that could position it as a tooth-friendlier alternative to conventional sweeteners. The catch is supply. Chemical synthesis routes to rare carbohydrates exist but tend to be multistep, wasteful and difficult to scale cleanly. Biocatalysis, in which an enzyme performs a single precise isomerization, is the greener route, and the enzyme of choice for converting abundant D-fructose into D-tagatose is tagatose 4-epimerase.

The problem with that enzyme class has always been durability. Free enzymes in solution are delicate protein machines; at the elevated temperatures that favor the fructose-to-tagatose equilibrium and suppress microbial contamination, they gradually unfold, aggregate and lose catalytic power. The research team, led by Xue Cai, Yuanshan Wang and Yuguo Zheng of Zhejiang University of Technology together with collaborators at Jiangxi Alpha Hi-tech Pharmaceutical, started from a thermostable tagatose 4-epimerase called TpT4Ease, originally identified in Thermotoga petrophila, a bacterium that thrives in hot environments. Even a thermostable enzyme, however, degrades at industrial operating temperatures over time, and a dissolved enzyme cannot simply be fished out of a reaction broth and used again.

The team’s solution was a two-step immobilization strategy. First, they treated the enzyme with glutaraldehyde, a bifunctional crosslinker that reacts with amino groups on the protein surface, creating covalent bridges both within and between enzyme molecules. Then they deposited the crosslinked enzyme onto LX-1000HA, a macroporous resin whose surface is decorated with amino groups. The glutaraldehyde chemistry locks the enzyme onto the resin through stable covalent bonds, while the resin’s large, open pores provide an enormous internal surface area for enzyme loading and allow sugar solutions to flow freely through the material. The resulting hybrid biocatalyst, designated TpT4Ease@LX-1000HA-GA, was characterized by circular dichroism spectroscopy and scanning electron microscopy, which confirmed that the protein retained its secondary structure and that the enzyme was successfully distributed across the resin matrix.

What makes the study particularly interesting is the kinetic analysis that followed. Immobilization is often a trade-off: anchoring a protein can stabilize it, but the same conformational constraints that prevent unfolding can also stiffen the enzyme’s natural breathing motions, slowing the catalytic cycle. That is precisely what the researchers observed. The conformational constraint imposed by the porous support slightly compromised the enzyme’s intrinsic turnover number, meaning each immobilized enzyme molecule worked a bit more slowly than its free counterpart. But the compensation was dramatic. By effectively preventing thermal unfolding, the support extended the enzyme’s half-life at seventy degrees Celsius from 3.3 hours for the free enzyme to 15.4 hours for the immobilized version, nearly a fivefold improvement in operational lifetime at the process temperature.

Storage stability improved as well, which matters enormously for any commercial deployment. A biocatalyst that loses activity while sitting on a warehouse shelf is a liability regardless of how well it performs on day one. The immobilized preparation retained its catalytic capacity far better than the free enzyme over storage, consistent with a well-established principle in enzyme technology: multipoint covalent attachment rigidifies a protein’s structure and raises the energetic barrier to the unfolding events that initiate irreversible deactivation. The finding echoes a broader literature on immobilization strategies, which has repeatedly shown that covalent attachment to appropriately functionalized supports is among the most reliable ways to engineer robust industrial biocatalysts.

The real test came in continuous operation. Rather than running batch reactions, the team packed the immobilized enzyme into a flow reactor and pumped fructose solution through it. Under optimized conditions, a 200 gram per liter fructose feed at seventy degrees Celsius and a flow rate of 0.5 milliliters per minute, the system achieved a D-tagatose yield of 17.3 percent. That number may look modest, but it must be read in context: the fructose-to-tagatose conversion is an equilibrium reaction, and the epimerization of one sugar isomer into another is inherently limited by thermodynamics. Continuous-flow operation offers a way to push past the limitations of batch processing, because the product is continuously removed from the catalyst bed, shifting the effective equilibrium and protecting the enzyme from prolonged exposure to reaction conditions.

Even more striking was the operational stability. After five consecutive cycles of continuous-flow bioconversion, the immobilized enzyme retained 90.6 percent of its original catalytic activity. In industrial terms, that is the difference between a laboratory curiosity and a process candidate. Reusability is the entire economic argument for immobilization: the enzyme is a cost, and every cycle of reuse dilutes that cost across more kilograms of product. A catalyst that surrenders less than ten percent of its activity over five full production cycles, while operating at seventy degrees Celsius in a concentrated sugar stream, demonstrates the kind of durability that process engineers need before they will commit to a biocatalytic route.

The study also fits into a larger shift in how bioprocesses are designed. Continuous processing has transformed pharmaceutical manufacturing over the past two decades, replacing large batch reactors with smaller, more controllable flow systems, and biocatalysis is following the same trajectory. Immobilized enzymes are the natural partners of flow chemistry, because they allow a solid catalyst phase to be held in place while liquid substrate streams through. The integrated immobilization-plus-continuous-flow architecture described in this work is a template that could extend beyond tagatose to other rare sugars and value-added carbohydrates, including D-allulose and related functional sweeteners that the food industry is actively pursuing.

There remain hurdles between this bench-scale system and a full industrial process. The yield of 17.3 percent per pass means that product recovery and substrate recycling will be essential to overall process economics, and longer-term deactivation studies beyond five cycles will be needed to establish realistic catalyst lifetimes. The work was supported by the National Natural Science Foundation of China, and the authors declare no competing financial interests. Still, the core message is hard to ignore: by understanding exactly what immobilization does to an enzyme, constraining its motion to buy thermal stability at a modest cost in turnover, the researchers turned a fragile protein into a reusable industrial catalyst. For a low-calorie sugar that could reshape how the food industry sweetens its products, that is a meaningful step from promise to production.

Subject of Research: Enzyme immobilization on amino-functionalized macroporous resin for continuous-flow biocatalytic production of D-tagatose from D-fructose

Article Title: Immobilization of a tagatose 4-epimerase on amino-functionalized macroporous resin and its application in bioconversion of D-fructose to D-tagatose

Article References: Cai, X., Wu, Y., Wu, A., Li, Q., Wang, C., Mi, W., Miao, Z., Wang, X., Liu, Z., Wang, Y., & Zheng, Y. (2026). Immobilization of a tagatose 4-epimerase on amino-functionalized macroporous resin and its application in bioconversion of D-fructose to D-tagatose. 3 Biotech, 16(9), Article 398. https://doi.org/10.1007/s13205-026-05035-z

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05035-z

Keywords: D-tagatose, tagatose 4-epimerase, enzyme immobilization, macroporous resin, glutaraldehyde crosslinking, continuous flow, biocatalysis, D-fructose, rare sugar, thermal stability, Thermotoga petrophila, biomanufacturing